Joseph C. Scodari Acquires 24,631 Shares of Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) Stock

Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) Director Joseph C. Scodari acquired 24,631 shares of the business’s stock in a transaction dated Monday, January 6th. The shares were bought at an average cost of $1.01 per share, for a total transaction of $24,877.31. Following the transaction, the director now directly owns 27,708 shares in the company, valued at approximately $27,985.08. This represents a 800.49 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Acurx Pharmaceuticals Trading Down 6.9 %

NASDAQ ACXP opened at $0.75 on Friday. The company has a market cap of $12.69 million, a P/E ratio of -0.69 and a beta of -1.71. The company has a fifty day simple moving average of $1.17 and a 200 day simple moving average of $1.77. Acurx Pharmaceuticals, Inc. has a 12-month low of $0.68 and a 12-month high of $5.28.

Acurx Pharmaceuticals (NASDAQ:ACXP) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.17) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.06. During the same quarter last year, the firm earned ($0.24) EPS. Sell-side analysts predict that Acurx Pharmaceuticals, Inc. will post -0.89 EPS for the current year.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reiterated a “buy” rating and issued a $12.00 price target on shares of Acurx Pharmaceuticals in a report on Tuesday, December 10th.

Institutional Trading of Acurx Pharmaceuticals

An institutional investor recently raised its position in Acurx Pharmaceuticals stock. Geode Capital Management LLC increased its stake in shares of Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) by 12.7% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 146,500 shares of the company’s stock after buying an additional 16,485 shares during the quarter. Geode Capital Management LLC owned 0.90% of Acurx Pharmaceuticals worth $278,000 at the end of the most recent quarter. Institutional investors own 11.53% of the company’s stock.

About Acurx Pharmaceuticals

Acurx Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections.